News Health & Medicine

CRISPR-edited immune cells for fighting cancer passed a safety test

The edited T cells caused no serious side effects in the trial’s 3 participants

cells

Multiple myeloma cancer cells (bluish cells) crowd out normal bone marrow cells. Researchers have used the gene editor CRISPR/Cas9 to engineer immune cells to fight cancer. The engineered cells just passed an important safety test in three cancer patients, including two with multiple myeloma.

Mayo Foundation for Medical Education and Research

By Tina Hesman Saey

- More than 2 years ago

Immune cells edited with CRISPR/Cas9 to fight cancer seem to be safe and long-lasting, a small safety test of the cells in three cancer patients at the University of Pennsylvania shows.